SpyGlass Pharma, Inc. director Geoffrey B. Pardo reports indirect beneficial ownership of 1,875,013 shares of the company’s Series D Preferred Stock. All shares of this preferred stock will automatically convert on a one-for-one basis into common stock prior to the closing of the company’s initial public offering of its common stock.
The shares are held by Cooperatieve Gilde Healthcare VG VI U.A., which is managed by Gilde Healthcare VG VI Management B.V. Gilde Healthcare VG VI Management B.V. has sole voting and dispositive power over these shares. Pardo, along with Edwin de Graaf and Pieter Van der Meer, may be deemed to share voting and dispositive power but each disclaims beneficial ownership except for any pecuniary interest.
SpyGlass Pharma director Elizabeth G. O'Farrell reported her beneficial ownership of stock options in the company. She holds a stock option for 65,976 shares of common stock with an exercise price of $7.11 per share, expiring on August 5, 2035.
According to the vesting terms, starting from a Vesting Commencement Date of August 6, 2025, 25% of the option vests on the one-year anniversary, with the remaining shares vesting in equal monthly installments over the following 36 months, subject to her continued service.
SpyGlass Pharma director Khan Bilal Arshad filed an initial ownership report showing his equity position in the company. He reports direct ownership of 5,450 shares of common stock and indirect beneficial ownership of 136,427 shares held by New World Medical, Inc., where he serves as Chief Executive Officer with voting and investment control.
He also holds stock options to purchase 11,992 shares of common stock at $2.18 per share and 48,533 shares at $7.11 per share. These options vest over time, subject to his continued service, with vesting schedules starting from September 20, 2023 and August 6, 2025.
SpyGlass Pharma, Inc. officer Chetan Pratap Pujara filed an initial statement of beneficial ownership as Chief R&D Officer. He reports three direct stock options to buy common stock covering 153,219, 31,397 and 34,798 shares at exercise prices of $2.18, $2.87 and $7.11 per share. Each option vests 25% on the one-year anniversary of its vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to his continued service.
SpyGlass Pharma Chief Operating Officer James Robert Dennewill Jr. filed an initial ownership report showing his equity stake in the company. He beneficially owns 96,022 shares of common stock directly, plus several stock option awards granted under the company’s equity incentive plan.
The options cover 78,494 shares at $2.18 per share expiring on October 5, 2033, 35,758 shares at $2.87 per share expiring on April 10, 2035, and 54,745 shares at $7.11 per share expiring on July 23, 2035. Each grant vests over four years, with 25% vesting one year after its vesting commencement date and the remainder in equal monthly installments, contingent on his continued service.
SpyGlass Pharma, Inc. Chief Financial Officer Jean-Frederic Viret reported his initial beneficial ownership on a Form 3. He holds a stock option covering 263,907 shares of common stock at an exercise price of $10.55 per share, expiring on November 12, 2035.
The option vests over time, starting from a vesting commencement date of January 1, 2026. Twenty-five percent of the shares vest on the one-year anniversary of that date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service.
SpyGlass Pharma, Inc. director and officer Malik Y. Kahook reports his initial ownership of company securities. He directly holds 873,978 shares of common stock. He also directly holds stock options to purchase 72,389 shares at $2.18, 191,874 shares at $2.87, and 170,475 shares at $7.11 per share.
Each option grant vests over four years under the company’s Amended and Restated 2019 Equity Incentive Plan. For each grant, 25% of the shares vest on the one-year anniversary of its Vesting Commencement Date, with the remaining shares vesting in equal monthly installments thereafter.
SpyGlass Pharma, Inc. director and Chief Executive Officer Patrick H. Mooney filed an initial ownership report, showing his beneficial holdings in the company. He directly owns 183,153 shares of common stock and holds several stock options to acquire additional common shares at exercise prices ranging from $0.35 to $7.11, with expiration dates extending to 2035. The options generally vest over four years, with 25% vesting after one year from each grant’s vesting commencement date and the remainder vesting monthly, contingent on his continued service to the company.